Author’s Reply to Srinivas: “Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection”

Samankaltaisia teoksia

• Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection
  Tekijä: Namour, Florence, et al.
  Julkaistu: (2015)
• Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor
  Tekijä: Namour, Florence, et al.
  Julkaistu: (2018)
• Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects
  Tekijä: Namour, Florence, et al.
  Julkaistu: (2016)
• Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK‐1 Inhibitor, After Short‐Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials
  Tekijä: Vanhoutte, Frédéric, et al.
  Julkaistu: (2017)
• JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib
  Tekijä: Traves, Paqui G, et al.
  Julkaistu: (2021)